Skip to main content

Drug Interactions between dofetilide and hydrocortisone / lidocaine / psyllium topical

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

lidocaine topical dofetilide

Applies to: hydrocortisone / lidocaine / psyllium topical and dofetilide

Coadministration of topical lidocaine with class III antiarrhythmics (e.g., amiodarone, dofetilide, sotalol) may lead to additive cardiovascular effects. Drug interaction studies evaluating class III antiarrhythmics with topical lidocaine formulations are unavailable. The degree of systemic absorption of topical lidocaine may be dependent on the duration of application and the applied surface area. Some authorities recommend increased clinical monitoring during concomitant use.

References (2)
  1. (2023) "Product Information. LMX 4 (lidocaine topical)." Ferndale Pharmaceuticals Ltd
  2. (2024) "Product Information. Xylocaine Topical (lidocaine topical)." Aspen Pharmacare Australia Pty Ltd

Drug and food interactions

Moderate

psyllium food

Applies to: hydrocortisone / lidocaine / psyllium topical

ADJUST DOSING INTERVAL: Bulk-forming laxatives such as guar gum, psyllium, polycarbophil, or methylcellulose may affect the bioavailability of concomitantly administered substances due to their effect on the rate of gastrointestinal transit and gastric emptying.

MANAGEMENT: In general, oral medications should be administered at least 2 hours before or 2 hours after dosing of the bulk-forming laxative.

References (1)
  1. (2001) "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceuticals
Minor

dofetilide food

Applies to: dofetilide

In vitro data suggest that grapefruit juice may inhibit the CYP450 3A4 first-pass metabolism of dofetilide. Decreased first-pass metabolism may increase dofetilide concentrations and increase the risk of QT interval prolongation and arrhythmias. The clinical significance is unknown, since dofetilide has a high oral bioavailability and a low affinity for CYP450 3A4. The manufacturer recommends caution.

References (1)
  1. (2001) "Product Information. Tikosyn (dofetilide)." Pfizer U.S. Pharmaceuticals

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer